FindTrial
Sign In

Metalyse 5 000 units (25 mg) powder for solution for injection

DRUG6 trials

Sponsors

Universitaetsklinikum Tuebingen AöR, Centre Hospitalier Regional Universitaire De Tours, Universitaetsklinikum Heidelberg AöR, Assistance Publique Hopitaux De Paris, University Medical Center Hamburg-Eppendorf

Conditions

Acute Ischemic StrokeAcute ischaemic stroke due to basilar artery occlusion.Acute non-arteritic central retinal artery occlusion (CRAO)Adult patients with a LVOS with large core within 9 hours of symptoms onset or last seen wellacute ischemic strokeor with a diffusion weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch in case of unknown onset.

Phase 2

Local tenecteplase applicatiOn subsequent to endovasCular recanalization in Anterior circuLation stroke - the LOCAL trial
Not yet recruitingCTIS2024-516544-26-00
Universitaetsklinikum Heidelberg AöRacute ischemic stroke
Target: 380Updated: 2025-12-01

Phase 3

Early Reperfusion Therapy with Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase III trial
RecruitingCTIS2023-507388-21-00
Universitaetsklinikum Tuebingen AöRAcute non-arteritic central retinal artery occlusion (CRAO)
Start: 2022-09-08Target: 1422Updated: 2025-05-28
Extending the time window for Tenecteplase by Effective RecanalizatioN of bAsilar artery occLusion in patients with POSTerior circulation stroke (POST ETERNAL)
Not yet recruitingCTIS2024-513444-28-00
Centre Hospitalier Regional Universitaire De ToursAcute ischaemic stroke due to basilar artery occlusion.
Target: 120Updated: 2024-11-19
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants – a multicentre randomised placebo-controlled clinical trial
Not yet recruitingCTIS2025-521762-99-00
University Medical Center Hamburg-Eppendorfacute ischemic stroke
Target: 668Updated: 2025-12-16
TENACITY – A Phase III, prospective, randomized, open-label, blinded endpoint assessment (PROBE) to assess efficacy and safety of i.v. tenecteplase vs standard of care in patients with acute ischemic stroke (including wake-up stroke), last known well >4.5 h with imaging evidence of salvageable ischemic tissue
Not yet recruitingCTIS2025-522542-40-00
Boehringer Ingelheim International GmbHAcute Ischemic Stroke
Target: 185Updated: 2026-03-12
“Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicentre Randomized Controlled Trial” THE IVT ALL IN TRIAL
Not yet recruitingCTIS2024-520414-21-00
Assistance Publique Hopitaux De ParisAdult patients with a LVOS with large core within 9 hours of symptoms onset or last seen well, or with a diffusion weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch in case of unknown onset.
Target: 486Updated: 2026-03-12

Related Papers

Early REperfusion therapy with intravenous alteplase for recovery of VISION in acute central retinal artery occlusion (REVISION): Study protocol of a phase III trial
International Journal of Stroke2024-04-0917 citations